International Psoriasis Council

Advancing Knowledge. Improving Care.

IEC & IPC Joint Symposium: Psoriasis or Dermatitis? When Boundaries Blur and Treatments Flip the Script

2026 ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY (AAD) | DENVER, COLORADO, UNITED STATES

March 26, 2026
 | 14:00-18:00 MDT
Location: Denver Convention Center, Room: Blue Bird Ballroom 3EF, Floor 3

Add this event to your calendar

Apple Google Outlook Outlook.com Office 365 Yahoo

This educational session will explore the clinical challenges of distinguishing between psoriasis and atopic dermatitis in non-classic
presentations, including psoriasiform spongiotic dermatitis and paradoxical drug reactions induced by biologic therapies like anti
TNF or IL-17 inhibitors. Through case studies and evidence-based discussions, participants will learn how to recognize subtle
diagnostic cues and apply the latest treatment strategies, incorporating histopathology and biomarkers into their treatment
decisions. Attendees will gain practical tools to improve diagnostic confidence, optimize patient outcomes, and navigate the
therapeutic complexities of inflammatory skin disease, including mechanistic insights for managing treatment-related rashes.

LEARNING OBJECTIVES

At the conclusion of this symposium, participants will be able to:

  1. Analyze the diagnostic challenges of distinguishing psoriasis from atopic dermatitis in non-classic clinical
    presentations, including recognition of psoriasiform spongiotic dermatitis, by identifying at least three
    distinguishing clinical features.
  2. Evaluate and apply advanced diagnostic strategies, such as histopathology and biomarker testing, to
    differentiate psoriasis, atopic dermatitis, and paradoxical drug reactions, demonstrating the ability to select at
    least two appropriate tools for challenging adult and pediatric cases.
  3. Design and implement evidence-based management plans for paradoxical psoriasiform and eczematous
    eruptions associated with biologic therapies, including TNF-α or IL-17 inhibitors, integrating mechanistic
    insights to optimize skin-related outcomes for patients with psoriasis, atopic dermatitis, or inflammatory bowel
    disease. 

Agenda

Welcome from the IEC & IPC
Alan Irvine, MD, DSc, Ireland
Bruce Strober, MD, PhD, United States

Diagnostic Challenges Between Atopic Dermatitis and Psoriasis
Andrew Pink, PhD, United Kingdom

Eczematous Reactions in Patients Receiving Treatments for Psoriasis

Clinical Presentation
Jason Hawkes, MD, MS, FAAD, United States

Clinical Approach
Kenneth Gordon, MD, United States

Q & A
Moderator: Bruce Strober, MD, PhD, United States

Psoriasiform Reactions in Patients Receiving Treatments for Atopic
Dermatitis & Prurigo Nodularis

Clinical Presentation
Shawn G. Kwatra, MD, United States

Clinical Approach
Yael Anne Leshem, MD, MCR, Israel

What is Psoriasiform Spongiotic Dermatitis? Navigating
Uncertainty Using Advanced Diagnostics

Kilian Eyerich, MD, PhD, Sweden

Q & A
Moderator: Amy Paller, MS, MD, United States

Anti-TNF-a Induced Skin Eruptions in Patients with Inflammatory Bowel Disease

Presentation and Clinical Approach in Adults
Lev Pavlovsky, MD, PhD, Israel

Presentation and Clinical Approach in Children
Amy Paller, MS, MD, United States

Mechanistic Aspects of Paradoxical Reactions and Iatrogenic Switches
Johann Gudjonsson, MD, PhD, United States

Final Q & A
Moderator: Yael Anne Leshem, MD, MCR, Israel

Closing Remarks
Alan Irvine, MD, DSc, Ireland
Bruce Strober, MD, PhD, United States

Program Chairs

Alan Irvine, MD, DSc

Trinity College Dublin, Children’s Health Ireland

Dublin, Ireland

Bio

Yael Anne Leshem, MD, MCR

Rabin Medical Center, Petah Tikva and Tel Aviv University

Tel Aviv, Israel

Bio

Amy Paller, MS, MD

Northwestern University Feinberg Medical School

Chicago, Illinois, United States

IPC Board Member

Bio

Bruce Strober, MD, PhD

Yale University and Central Connecticut Dermatology

Cromwell, Connecticut, United States

IPC President

Bio

Program Faculty

Kilian Eyerich, MD, PhD

University of Freiburg

Freiburg, Germany

IPC Councilor

Bio

Kenneth Gordon, MD

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

IPC Councilor

Bio

Johann Gudjonsson, MD, PhD

University of Michigan, Department of Dermatology

Ann Arbor, Michigan, United States

IPC Board Member

Bio

Jason Hawkes, MD, MS, FAAD

Oregon Medical Research Center (OMRC)

Portland, Oregon, United States

IPC Councilor

Bio

Shawn Kwatra, MD

Johns Hopkins University School of Medicine

Baltimore, Maryland, United States

Bio

Lev Pavlovsky, MD, PhD

Tel Aviv University

Petah-Tikva, Israel

IPC Councilor

Bio

Andrew Pink, PhD

St. John’s Institute of Dermatology, Guy & St. Thomas’ NHS Foundation Trust

London, United Kingdom

IPC Councilor

Bio

This symposium is supported in part by:

Amgen’s Manufacturing is Worldwide Pioneer in Biotechnology

These sponsorships are provided exclusively to the IPC.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026